# Delcath Systems (DCTH) Stock Price, News & Analysis
Canonical URL: https://biopharmsignal.com/company/DCTH
## Company Profile
- Ticker: DCTH
- Exchange: NASDAQ
- Sector: Biopharma
- Location: United States
- Tags: MedTech, Oncology
## Stock Data
- Close: 17.22 USD
- Market cap: 363512942.90999997 USD
- Last updated: 2026-08-11
## Business Overview
### Interventional Oncology
Delcath Systems develops liver-directed therapies for primary and metastatic liver cancers. Its technology isolates hepatic circulation so high-dose chemotherapy can be delivered to the liver while limiting systemic exposure.
### HEPZATO KIT
HEPZATO KIT combines melphalan with the company's percutaneous hepatic-perfusion system. It is approved in the United States for selected adults with unresectable hepatic-dominant metastatic uveal melanoma. CHEMOSAT is the European commercial version of Delcath's hepatic-delivery platform. The company supports adoption through treatment-center activation, clinician training and procedure-based consumable sales.
## Why The Stock Is Moving

As of Aug 11, 2026, DCTH closed up 3.30% at $17.22. No new same-company headline was identified in the current news window.

## Recent News
- 2026-08-06 12:01 EST — [Delcath Systems Reports Second Quarter 2026 Results and Business Highlights](https://biopharmsignal.com/news/DCTH/delcath-systems-reports-second-quarter-2026-results-and-business-highlights-a6c7e160) — Source: Delcath Systems
- 2026-07-28 20:01 EST — [Delcath Systems to Participate at the Canaccord Genuity 46th Annual Growth Conference](https://biopharmsignal.com/news/DCTH/delcath-systems-to-participate-at-the-canaccord-genuity-46th-annual-growth-confe-67f1478e) — Source: Delcath Systems
- 2026-07-23 20:01 EST — [Delcath Systems to Host Second Quarter 2026 Earnings Call](https://biopharmsignal.com/news/DCTH/delcath-systems-to-host-second-quarter-2026-earnings-call-3175cc66) — Source: Delcath Systems
- 2026-07-16 20:01 EST — [Delcath Systems, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)](https://biopharmsignal.com/news/DCTH/delcath-systems-inc-announces-inducement-grants-under-nasdaq-listing-rule-5635-c-15301d33) — Source: Delcath Systems
- 2026-07-09 12:00 EST — [Delcath Systems Announces First Patient Dosed in Phase 2 Clinical Trial of HEPZATO™ in Liver-Dominant Metastatic Breast Cancer](https://biopharmsignal.com/news/DCTH/delcath-systems-announces-first-patient-dosed-in-phase-2-clinical-trial-of-hepza-10c88413) — Source: Delcath Systems